Spojené štáty - angličtina - NLM (National Library of Medicine)

remedyrepack inc. - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - when oral therapy is not feasible, the intramuscular use of celestone ® soluspan ® injectable suspension is indicated as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. acq

Spojené štáty - angličtina - NLM (National Library of Medicine)

organon llc - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - when oral therapy is not feasible, the intramuscular use of celestone® soluspan® injectable suspension is indicated as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. acquired (autoimmune) hemolytic anemia, diamond-blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. for palliative management of leukemias and lymphomas. acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. the intra-articular or soft tissue administration of celestone soluspan injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. the intralesional administration of celestone soluspan injectable suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. celestone soluspan injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). celestone® soluspan® injectable suspension is contraindicated in patients who are hypersensitive to any components of this product (see description ). intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.

Spojené štáty - angličtina - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid direct infant exposure [see use in specific populations ( error! hyperlink reference not valid. )] .

Spojené štáty - angličtina - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breast

Spojené štáty - angličtina - NLM (National Library of Medicine)

warrick pharmaceuticals corporation - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - ointment - 0.5 mg in 1 g - augmented betamethasone dipropionate ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. augmented betamethasone dipropionate ointment is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

Spojené štáty - angličtina - NLM (National Library of Medicine)

merck sharp & dohme corp. - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m) - gentamicin 3 ug in 1 ml - indications gentocin durafilm ophthalmic solution is indicated for the treatment of external eye infections and inflammation in dogs. clinical reports indicate it is useful for the management of some cases of pigmentary keratitis and pannus. temporary remission of some of the pathological lesions of the aforementioned conditions have been noted following therapy with gentocin durafilm ophthalmic solution. contraindications corticosteroids are contraindicated in initial treatment of corneal ulcers. gentocin durafilm ophthalmic solution is contraindicated in ocular conditions where there is deep ulceration without vascularization and in conditions of viral origin before healing has commenced.

Spojené štáty - angličtina - NLM (National Library of Medicine)

elanco us inc. - florfenicol (unii: 9j97307y1h) (florfenicol - unii:9j97307y1h), terbinafine (unii: g7riw8s0xp) (terbinafine - unii:g7riw8s0xp), betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m) - do not use in dogs with known tympanic perforation (see precautions ). do not use in dogs with a hypersensitivity to florfenicol, terbinafine or corticosteroids.

Spojené štáty - angličtina - NLM (National Library of Medicine)

dechra veterinary products - florfenicol (unii: 9j97307y1h) (florfenicol - unii:9j97307y1h), terbinafine (unii: g7riw8s0xp) (terbinafine - unii:g7riw8s0xp), betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m) - do not use in dogs with known tympanic perforation (see precautions ). do not use in dogs with a hypersensitivity to florfenicol, terbinafine or corticosteroids.

Európska únia - angličtina - EMA (European Medicines Agency)

elanco europe ltd - terbinafine / florfenicol / betamethasone acetate - otologicals-corticosteroids and antiinfectives in combination - dogs - treatment of acute otitis externa

Izrael - angličtina - Ministry of Health

glaxo smith kline (israel) ltd - betamethasone as valerate - cream - betamethasone as valerate 0.1 %w/w - betamethasone - betamethasone - betamethasone valerate is a potent topical corticosteroid indicated for adults, elderly and children over 1 year for the relief of the inflammatory and pruritic manifestations of steroid responsive dermatoses.